SAS Output

21-JUL-2017 18:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9252 799 420 203 68 16 BREAST
        9252 799 420 203 68 16  
 
  2 Y 2 Chemo and Endocrine Therapy 2493 272 138 71 22 6  
      3 Endocrine Therapy Alone 2483 276 145 71 21 7  
        4976 548 283 142 43 13  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 647 222 114 53 18 7 BREAST
      2 Blinded drug + Endocrine 641 213 111 50 17 4  
        1288 435 225 103 35 11  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization: Surgery 1 0 0 0 0 0 SURV
      2 Randomization: Non-surgical M 1 1 1 1 0 0  
      3 Patient Choice: Surgery 29 19 11 6 1 0  
      4 Patient Choice: Non-surgical M 61 36 23 12 2 0  
        92 56 35 19 3 0  
 
S1400I-Non-Match: Nivo + Ipi vs Nivo 1 Y 1 Nivolumab + Ipilimumab 103 64 22 10 2 1 LUNG
      2 Nivolumab 108 72 29 13 4 1  
        211 136 51 23 6 2  
 
S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 1 Y 1 Tissue for PD-L1 testing 1302 1024 538 254 94 24 MELAN
        1302 1024 538 254 94 24  
 
  2 Y 2 FDA approved regimen 605 483 267 126 48 15  
      3 MK-3475 (Pembrolizumab) 589 474 249 115 40 8  
        1194 957 516 241 88 23  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 259 259 197 99 34 8 CCD
      2 Site randomized: Control 128 128 123 75 33 8  
      3 SiteRand Int Risk: CSF 152 152 134 75 28 6  
      4 SiteRand Int Risk: No CSF 100 100 93 66 17 2  
        639 639 547 315 112 24  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 75 72 57 35 12 0 CCD
        75 72 57 35 12 0  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 49 49 47 32 11 2 BREAST
        49 49 47 32 11 2  
 
  2 Y 2 Observation 22 22 22 18 6 3  
      3 MK-3475 (Pembrolizumab) 19 19 19 13 3 1  
        41 41 41 31 9 4  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 5 5 5 3 1 0 GU
      2 Tokyo-172 BCG 4 4 4 3 1 1  
      3 Prime + Tokyo-172 BCG 4 4 4 3 1 1  
        13 13 13 9 3 2  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 376 139 61 34 16 7 PREV
        376 139 61 34 16 7  
 
  1 Y 1 Blinded drug 42 18 10 7 0 0  
      2 Blinded drug 36 12 6 0 0 0  
      3 Blinded drug 35 12 4 0 0 0  
      4 Blinded drug 41 16 12 6 1 0  
        154 58 32 13 1 0